Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
17 Septiembre 2023 - 11:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating novel, small molecule
drugs for viral infections, today announced that data for EDP-323,
its oral, once-daily, L-protein inhibitor in development for the
treatment of respiratory syncytial virus (RSV), will be presented
at the 9th European Scientific Working Group on Influenza (ESWI)
Influenza Conference on September 17-20, 2023 at the Palacio de
Congresos de Valencia in Valencia, Spain.
Date/Time: Sunday, September 17, 2023, from 20:00 – 21:00
CEST / 2:00 – 3:00 PM EDT (Sneak Peak) Date/Time: Monday,
September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT
Abstract Number: 663 Poster Title: “EDP-323, a
First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the
Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects
and Correlation with In Vitro Antiviral Activity” Location:
Poster Hall Exhibit Presenter: Kimberly Mills, PharmD
Further information about the ESWI Influenza Conference can be
found here.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections. Enanta’s
research and development programs include clinical candidates for
the following disease targets: respiratory syncytial virus (RSV),
SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also
conducting research on a single agent targeting both RSV and human
metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De May 2023 a May 2024